506 IMMUNOREACT 10: INFLUENCE OF BMI IN THE IMMUNOLOGICAL MICROENVIRONMENT OF PERITUMORAL HEALTHY MUCOSA IN RECTAL ADENOCARCINOMA
Chiara Vignotto(University of Padua), Marco Scarpa(University of Padua), Giulia Becherucci(University of Padua), Salvatore Pucciarelli(Azienda Ospedale - Università Padova), Quoc Riccardo Bao(University of Padua), Ignazio Castagliuolo(University of Padua), Maurizio Zizzo(Azienda Sanitaria Unità Locale di Reggio Emilia), Ivana Cataldo(Ospedale SS. Annunziata), Angelo Paolo Dei Tos(University of Padua), Melania Scarpa(University of Padua), Francesca Bergamo(Istituto Oncologico Veneto), Cesare Ruffolo(Ca' Foncello Hospital), Beatrice Salmaso(Ospedale Santa Maria della Misericordia di Rovigo), Astghik Stepanyan(University of Padua), Vittorina Zagonel(Istituto Oncologico Veneto), Marco Massani(AULSS 2 Marca Trevigiana), Silvia Negro(University of Padua), Stefano Brignola(University of Padua), Valentina Chiminazzo(University of Padua), Tommaso Stecca(Ca' Foncello Hospital), Antonio Scapinello(Istituto Oncologico Veneto), Matteo Fassan(University of Padua), Luca Dal Santo(University of Padua), Romeo Bardini(University of Padua), Pierluigi Pilati(Istituto Oncologico Veneto), Francesco Cavallin, Marco Agostini(University of Padua), Licia Laurino(University of Padua), Gianluca Businello(University of Padua), Gaya Spolverato(University of Padua), Federico Scognamiglio(University of Padua), Andromachi Kotsafti(Istituto Oncologico Veneto), Carlotta Ceccon(University of Padua), Ottavia De Simoni(Istituto Oncologico Veneto), Giovanni Pirozzolo(Ottawa Hospital), Barbara Di Camillo(University of Padua), Alfonso Recordare(Ca' Foncello Hospital), Imerio Angriman, Boris Franzato(Istituto Oncologico Veneto), Isacco Maretto(University of Padua), Vincenza Guzzardo(University of Padua), Anna Pozza(University of Padua), Andrea Porzionato(University of Padua), Nicole Maddalena Maturi, Roberta Salmaso
Cited by 0
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
|Science|2018|2.1k
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k